+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen



High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen



European Respiratory Journal 2018



Background: South African patients with rifampicin-resistant tuberculosis and resistance to fluoroquinolones and/or injectables (pre/XDR-TB) were granted access to bedaquiline through a Clinical Access Programme with strict inclusion and exclusion criteria.Methods: Pre/XDR-TB and XDR-TB patients were treated with 24 weeks bedaquiline within an optimised, individualised background regimen that could include levofloxacin, linezolid and clofazimine as needed.Results: 200 patients were enrolled: 87 (43.9%) with XDR-TB, 99 (49.3%) were female, median age 34 years (IQR 27, 42). 134 (67.0%) were living with HIV; median CD4+ 281 (IQR 130; 467) and all on antiretroviral therapy.16/200 patients (8.0%) did not complete 6 months of bedaquiline of which 8 were lost to follow up, 6 died, 1 stopped for side effects and 1 patient was diagnosed with drug-sensitive TB.146/200 (73.0%) patients had favourable outcomes: 139/200 were cured (69.5%) and 7 completed treatment (3.5%). 25 died (12.5%), were lost from treatment (10.0%), 9 had treatment failure (4.5%).22 adverse events were attributed to bedaquiline: including QTcF >500 ms (n=5), QTcF increase >50 ms from baseline (n=11), paroxysmal atrial flutter (n=1).Conclusion: Bedaquiline added to an optimised background regimen was associated with a high rate of successful treatment outcomes for this MDR-TB and XDR-TB cohort.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065803478

Download citation: RISBibTeXText

PMID: 30361246

DOI: 10.1183/13993003.01528-2018


Related references

Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clinical Infectious Diseases 60(2): 188-194, 2015

Cost-Effectiveness of Adding Bedaquiline To Background Drug Regimens For The Treatment of Multidrug-Resistant And Extensively-Resistant Tuberculosis In Italy. Value in Health 19(7): A553-A554, 2016

Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. European Respiratory Journal 47(2): 564-574, 2016

Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: report from Iran. Microbial Drug Resistance 16(1): 81-86, 2010

Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Clinical Infectious Diseases 62(9): 1188-1190, 2017

Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review. Journal of Thoracic Disease 9(7): 2093-2101, 2017

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review. International Journal of Molecular Sciences 18(2), 2017

Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea. Annals of Laboratory Medicine 38(6): 563-568, 2018

Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis. European Respiratory Journal 49(5), 2018

Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease 23(1): 99-104, 2019

Treatment of multidrug-resistant and extensively drug-resistant tuberculosis in adolescent patients. Pediatric Infectious Disease Journal 33(6): 657-659, 2015

Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa. Infection, Genetics and Evolution 12(4): 686-694, 2012

Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clinical Infectious Diseases 47(4): 496-502, 2008

Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. Antimicrobial Agents and ChemoTherapy 53(8): 3353-3356, 2009

Treatment of multidrug-resistant and extensively drug-resistant tuberculosis: current status and future prospects. Expert Review of Clinical Pharmacology 2(4): 405-421, 2009